Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells

Cell Death and Disease

Volumn 6, Issue 4, 2015, Pages

  Li, X ^a,b   Gao, D ^a   Wang, H ^a   Yang, J ^a   Yan, X ^a   Liu, Z ^a   Ma, Z ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BETA CATENIN; PROTEIN P66SHC; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; HOMEODOMAIN PROTEIN; SHC SIGNALING ADAPTOR PROTEIN; SHC TRANSFORMING PROTEIN 1; SHC1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; ZEB1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE REPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; NEGATIVE FEEDBACK; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; FEEDBACK SYSTEM; GENETICS; HEP-G2 CELL LINE; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEEDBACK, PHYSIOLOGICAL; HEP G2 CELLS; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; SHC SIGNALING ADAPTOR PROTEINS; SRC HOMOLOGY 2 DOMAIN-CONTAINING, TRANSFORMING PROTEIN 1; TRANSCRIPTION FACTORS; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84989932476     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.74     Document Type: Article

References (49)

1. Zimmermann S, Dziadziuszko R, Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev 2014; 40: 716-722.
2. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13: 97-110.
3. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-826.
4. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta 2009; 1796: 293-308.
5. Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci 2014; 35: 479-488.
6. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178-196.
7. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
8. Meredith Jr JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993; 4: 953-961.
9. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005; 65: 5991-5995 discussion 5995.
10. Kumar S, Park SH, Cieply B, Schupp J, Killiam E, Zhang F et al. A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol Cell Biol 2011; 31: 4036-4051.
11. Brabletz T. To differentiate or not-routes towards metastasis. Nat Rev Cancer 2012; 12: 425-436.
12. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-626.
13. Gilmore AP. Anoikis. Cell Death Differ 2005; 12: 1473-1477.
14. Katsuno Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 2013; 25: 76-84.
15. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
16. Ventura A, Luzi L, Pacini S, Baldari CT, Pelicci PG. The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter. J Biol Chem 2002; 277: 22370-22376.
17. Hardy WR, Li L, Wang Z, Sedy J, Fawcett J, Frank E et al. Combinatorial ShcA docking interactions support diversity in tissue morphogenesis. Science 2007; 317: 251-256.
18. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G et al. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J 1997; 16: 706-716.
19. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402: 309-313.
20. Ma Z, Myers DP, Wu RF, Nwariaku FE, Terada LS. p66Shc mediates anoikis through RhoA. J Cell Biol 2007; 179: 23-31.
21. Du W, Jiang Y, Zheng Z, Zhang Z, Chen N, Ma Z et al. Feedback loop between p66(Shc) and Nrf2 promotes lung cancer progression. Cancer Lett 2013; 337: 58-65.
22. Ma Z, Liu Z, Wu RF, Terada LS. p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior. Oncogene 2010; 29: 5559-5567.
23. Li X, Xu Z, Du W, Zhang Z, Wei Y, Wang H et al. Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells. Cancer Cell 2014; 25: 575-589.
24. Frisch SM, Schaller M, Cieply B. Mechanisms that link the oncogenic epithelialmesenchymal transition to suppression of anoikis. J Cell Sci 2013; 126: 21-29.
25. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelial-mesenchymal transition. Cancer Res 2008; 68: 9574-9577.
26. Smit MA, Peeper DS. Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis. Oncogene 2011; 30: 3735-3744.
27. Takai E, Tsukimoto M, Kojima S. TGF-beta1 downregulates COX-2 expression leading to decrease of PGE2 production in human lung cancer A549 cells, which is involved in fibrotic response to TGF-beta1. PLoS One 2013; 8: e76346.
28. Zhang J, Tian XJ, Zhang H, Teng Y, Li R, Bai F et al. TGF-beta-induced epithelial-tomesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci Signal 2014; 7: ra91.
29. Risolino M, Mandia N, Iavarone F, Dardaei L, Longobardi E, Fernandez S et al. Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-beta- SMAD3 pathway in non-small cell lung adenocarcinoma. Proc Natl Acad Sci USA 2014; 111: E3775-E3784.
30. Zheng Z, Yang J, Zhao D, Gao D, Yan X, Yao Z et al. Downregulated adaptor protein p66(Shc) mitigates autophagy process by low nutrient and enhances apoptotic resistance in human lung adenocarcinoma A549 cells. FEBS J 2013; 280: 4522-4530.
31. Shah PP, Lockwood WW, Saurabh K, Kurlawala Z, Shannon SP, Waigel S et al. Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells. Oncogene 2014; 21: 97.
32. Drake LE, Macleod KF. Tumour suppressor gene function in carcinomaassociated fibroblasts: from tumour cells via EMT and back again? J Pathol 2014; 232: 283-288.
33. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
34. McClatchey AI, Yap AS. Contact inhibition (of proliferation) redux. Curr Opin Cell Biol 2012; 24: 685-694.
35. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16: 488-494.
36. Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta- SMAD pathway. Dev Cell 2010; 19: 831-844.
37. Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of Snail in EMT and tumorigenesis. Curr Cancer Drug Targets 2013; 13: 963-972.
38. Meng X, Kong DH, Li N, Zong ZH, Liu BQ, Du ZX et al. Knockdown of BAG3 induces epithelial-mesenchymal transition in thyroid cancer cells through ZEB1 activation. Cell Death Dis 2014; 5: e1092.
39. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
40. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61-74.
41. Magenta A, Cencioni C, Fasanaro P, Zaccagnini G, Greco S, Sarra-Ferraris G et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 2011; 18: 1628-1639.
42. Afanas'ev I. Reactive oxygen species and age-related genes p66shc, Sirtuin, FOX03 and Klotho in senescence. Oxid Med Cell Longev 2010; 3: 77-85.
43. Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 2005; 24: 425-439.
44. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13: 555-562.
45. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett 2008; 272: 177-185.
46. Debnath J. p66(Shc) and Ras: controlling anoikis from the inside-out. Oncogene 2010; 29: 5556-5558.
47. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H et al. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 2008; 68: 5104-5112.
48. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004; 64: 9027-9034.
49. Liu Z, Garrard WT. Long-range interactions between three transcriptional enhancers, active Vkappa gene promoters, and a 3' boundary sequence spanning 46 kilobases. Mol Cell Biol 2005; 25: 3220-3231.